TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41614

Peptide_Name

RB4

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 24-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

MADSERLSAPGCWAACTNFSRTRK-NH2

FASTA

>TPDB41614|Anticancer|length=24
MADSERLSAPGCWAACTNFSRTRK-NH2

Formula C110H176N36O35S3

Absent Amino Acids QHIYV

Common Amino Acids A

Mass 2659.01

PI 9.14

Basic Residues 4

Acidic Residues 2

Hydrophobic Residues 8

Net Charge +2

Boman Index 3.29

Hydrophobicity -0.579

Aliphatic Index 32.92

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 5625

Absorbance 280nm 211.55

Polar Residues 8

number

4

A

3

R

1

N

1

D

2

C

1

E

0

Q

1

G

0

H

0

I

1

L

1

K

1

M

1

F

1

P

3

S

2

T

1

W

0

Y

0

V

Amino Acid Distribution

A: 4 R: 3 N: 1 D: 1 C: 2 E: 1 Q: 0 G: 1 H: 0 I: 0 L: 1 K: 1 M: 1 F: 1 P: 1 S: 3 T: 2 W: 1 Y: 0 V: 0

Length

24

Formula

C110H176N36O35S3

Mass

2659.01

PI

9.14

Net Charge

+2

Boman Index

3.29

Hydrophobicity

-0.579

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

Derived from protein PLP2

Evidence 1 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 0.263 ± 0.585 mol/L × 10-3

Detail Source Activity Anticancer

Activity Measurement 0.263

Target

Cancer Type Skin Cancer

Cell Line B16-F10-Nex 2

Tissue Affected Skin

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 0.525 ± 0.160 mol/L × 10-3

Detail Source Activity Anticancer

Activity Measurement 0.525

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 3 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 0.427 ± 0.053 mol/L × 10-3

Detail Source Activity Anticancer

Activity Measurement 0.427

Target

Cancer Type Brain Tumor

Cell Line U-87

Tissue Affected Brain

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 4 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 0.744 ± 0.208 mol/L × 10-3

Detail Source Activity Anticancer

Activity Measurement 0.744

Target

Cancer Type Skin Cancer

Cell Line A-2058

Tissue Affected Skin

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 5 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 0.724 ± 0.340 mol/L × 10-3

Detail Source Activity Anticancer

Activity Measurement 0.724

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022